INVESTORS & MEDIA

Press Releases


Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September

September 2, 2020 at 7:00 AM EDT

DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced its participation in the following upcoming investor conferences:

  • 2020 Wells Fargo Virtual Healthcare Conference
    Date: Thursday, September 10, 2020
    Time: 12:40 – 1:10 PM ET

  • H.C. Wainwright Annual Global Investment Conference
    Date: Monday, September 14, 2020
    Time: 1:30 – 1:50 PM ET
     
  • Morgan Stanley Global Healthcare Conference
    Date: Thursday, September 17, 2020
    Time: 8:45 – 9:15 AM ET

Live webcasts of each presentation will be accessible on the Company’s website, www.PrecisionBiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following the presentations.

About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. Elo Life Systems is a wholly-owned subsidiary of Precision BioSciences also using ARCUS to benefit human health and wellness with novel food products that enhance the nutrition and diversity of global food supply. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.messier@precisionbiosciences.com

Josh Rappaport
Stern Investor Relations
josh.rappaport@sternir.com